Simplifying Global Compliance
FDAnews Device Daily Bulletin
EnteroMedics' ReCharge Trial Demonstrates Statistically Significant Weight Loss in Obesity But Does Not Meet Predefined Efficacy Endpoints
Feb. 11, 2013
EnteroMedics, the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, announced results from its randomized ReCharge Pivotal Trial of VBLOC vagal blocking therapy for the treatment of obesity.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing